Sun Pharma's Q1 margins likely to be hit on elevated input costs: Analysts
Sun Pharma Q1FY23 results: Prabhudas Lilladher foresees the company's net profit to rise 27 per cent year-on-year (YoY) to Rs 1,786 crores from Rs 1,445 crores in the year-ago quarter.
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to territory expansion of license and supply agreement between Sun Pharma and Cosmo for WINLEVI(r) SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
Sun Pharma, Glenmark recall products in US due to manufacturing issues
Leading drug makers Sun Pharma and Glenmark are recalling products in the US, the world's largest market for medicines, due to lapses in the manufacturing process. As per the latest enforcement report by the US Food and Drug Administration (USFDA), a US-based unit of Sun Pharma is recalling 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males, in the American market. According to the US health regulator, the Mumbai-based drug major is recalling the affected lot due to "water leakage" leading to deviation from current good manufacturing practices (cGMP). The company is also recalling 27 vials of the same medication due to cGMP deviations, USFDA said. "Manufacturing deviations were reported due to an abnormal appearance on parts of machinery," it added. The affected lot was produced at Sun Pharma's Halol (Gujarat) based manufacturing plant. New Jersey-based Sun Pharmaceutical Industries Inc, a unit of the company, initiated the Class II... SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0880 Name of the Signatory :- Anoop DeshpandeDesignation :- Company Secretary and Compliance Officer
Sun Pharma, Axis Bank among 7 short term trading ideas by experts
The market opened with strong gains despite negative global cues. US stocks closed in the red as retail inflation in the US accelerated to 9.1% which is the highest in 41 years. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for financial results for the first quarter ending June 30, 2022 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2022
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Top Indian pharma stocks to buy: Here are BNP Paribas' picks
Sharing its top stock picks, BNP Paribas said it continues to prefer Sun Pharma and Aurobindo Pharma